News
New Weight Loss Pill From Eli Lilly Shows Promise in Early Study
FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an average 27.3 pounds, or 12.4% of their body weight, over 72 weeks.
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
Pharmaceutical Technology on MSN23h
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...
Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback